W eng Xianding is a prominent investor and the majority shareholder of Shenzhen New Industries Biomedical Engineering (Snibe), a leading Chinese medical device manufacturer. He has a background in finance and regulation, having served as the first representative of the China Securities Regulatory Commission (CSRC) in Shenzhen in the early 1990s. He later transitioned to the private sector, founding investment firm New Industries Investment, which became the controlling entity of Snibe.

Snibe specializes in clinical laboratory instruments and in vitro diagnostic (IVD) reagents, and was the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay analyzer. Under Weng's strategic oversight as a key shareholder, the company went public on the Shenzhen Stock Exchange in 2020. His investment acumen identified the high-growth potential of the biomedical sector early on, positioning Snibe as a global competitor in the diagnostics market.